The antimicrobial peptide DEFA5 has emerged as a promising biomarker for distinguishing IBD subtypes because its expression is restricted to colonic IBD conditions and associated with Paneth ileal-cell metaplasia, a feature more common in Crohn’s colitis than ulcerative colitis [4,5]. This evidence concerns the gene DEFA5 and ulcerative colitis.